Cradle vs Insilico Medicine
A side-by-side comparison of Cradle and Insilico Medicine, two Science tools, drawn from Ignaite's continuously-verified listings.
Compared from listings verified as of
Insilico Medicine
ScienceGenerative AI drug discovery — the end-to-end Pharma.ai suite.
View Insilico MedicineAt a glance
| Attribute | Cradle | Insilico Medicine |
|---|---|---|
| Category | Science | Science |
| Pricing | PAID | PAID |
| License | Proprietary | Proprietary |
| Deployment | Cloud | Cloud |
| Platforms (differs) | Web | Web, API |
| Model support (differs) | — | Self-contained (on-device) |
| Vendor (differs) | Cradle | Insilico Medicine |
| Capabilities (differs) |
|
|
The honest brief
Cradle
Self-serve web SaaS for protein engineering with per-customer models and an in-house wet lab — a usable product where most rivals are partnership-only.
- Self-serve web platform
- Multi-property optimization
- Per-customer models on your lab data
- Customers keep IP, no royalties
- Enterprise sales-led pricing
- No public free tier
- Needs customer wet-lab data
- Not a downloadable model
Insilico Medicine
Sells its full discovery pipeline as licensed software — pharma can run PandaOmics and Chemistry42 directly, not just via a partner-only program.
- End-to-end Pharma.ai software suite
- Used by most of the top-20 pharma
- First AI-designed drug into Phase 2
- $2.75B Eli Lilly partnership
- Enterprise-only, opaque pricing
- Built for pharma R&D, not general users
- No approved drug yet
- Heavy domain expertise required
When to pick which
Both cover Protein design.
Pick Cradle if you need Fine-tuning / training.
- Fine-tuning / training (secondary capability)
Pick Insilico Medicine if you need Drug target discovery and Molecular design.
- Drug target discovery (primary capability)
- Molecular design (secondary capability)
Cradle leans on Protein design as a headline capability; Insilico Medicine treats it as secondary.
- Protein design (primary capability)
They also differ on:
- Platforms
- Web · Web, API